May 3rd 2024
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Melanoma diagnosis by physician or PA not always straightforward
June 7th 2018In a comparison of the performance between physician assistants and dermatologists, physician assistants may have lower diagnostic accuracy for melanoma than dermatologists, suggests a study published in JAMA Dermatology. The AAPA and SDPA question the use of the NNB ratio to determine diagnostic accuracy.
Skin cancer prevention messaging works (for some)
May 28th 2018Studies have shown that melanoma incidence rates among non-Hispanic whites have been rising in recent years, which is true ― to a degree, according to a research letter published in March in JAMA Dermatology. The rates are indeed rising for those younger than 15 years old and older than 45 years old. However, the analysis highlights a big dip in melanoma cases for those between 15-44 years.
Managing hedgehog therapies for basal cell carcinoma
February 19th 2018While the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Revised melanoma staging criteria
November 4th 2017Staging system is derived from a new dataset of patients from 10 cancer centers around the world. Dermatologists should consider AJCC tumor characteristics as well as other factors in risk assessment, counseling, and follow-up plans for patients. Update takes effect in January 2018.
Repurposed antifungal exhibits promising results
November 2nd 2017A novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.
Kyocera develops image recognition technology for skin disease identification
October 16th 2017Kyocera Communication Systems, a subsidiary of Kyocera, is teaming with the University of Tsukuba to created artificial intelligence (AI)-based technology that could identify skin cancers and other skin diseases.
ECP may prevent mycosis fungoides progression
May 2nd 2017Extracorporeal photopheresis is underused for early-stage mycosis fungoides. ECP is capable of correcting the cytokine imbalance seen in patients with MF and results in an increase of Th1 cytokines. Clinicians should consider more frequent use in select patients